Mycophenolate mofetil for ocular inflammation. - Wikidata - thesis-toulmin - TriplyDB

Mycophenolate mofetil for ocular inflammation.

Mycophenolate mofetil for ocular inflammation.

http://www.wikidata.org/entity/Q33521396

about

Emerging drugs for uveitis Involvement of B cells in non-infectious uveitis New Immunosuppressive Therapies in Uveitis Treatment The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Adverse effects of systemic immunosuppression in keratolimbal allograft.Uveodermatologic syndrome concurrent with keratoconjunctivitis sicca in a miniature poodle dog.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis.Pharmacotherapy for uveitis: current management and emerging therapy.Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.Success with single-agent immunosuppression for multifocal choroidopathies.Review of Systemic Immunosuppression for Autoimmune Uveitis Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.Response of pediatric uveitis to tumor necrosis factor-α inhibitors.Mycophenolate mofetil monotherapy in the management of paediatric uveitis.Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.More than meets the eye.Clinical trials in noninfectious uveitis Corticosteroid-sparing therapy: practice patterns among uveitis specialists High-dose intravenous corticosteroids for ocular inflammatory diseases.Remission of Intermediate Uveitis: Incidence and Predictive Factors Esophageal Cicatricial Pemphigoid as an Isolated Involvement Treated with Mycophenolate Mofetil Clinical features and visual outcomes of scleritis patients presented to tertiary care eye centers in Saudi Arabia.Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Statin use and ocular inflammatory disease risk.Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.Morphological assessment of the retina in uveitis.New options for uveitis treatment.Punctate inner choroidopathy and optic neuropathy: simultaneous presentation in a patient - a case report Pharmacotherapy of scleritis: current paradigms and future directions.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.Road to remission: a comprehensive review of therapy in uveitis.Mycophenolate mofetil in the treatment of chronic non-infectious, non-necrotizing scleritis.The role of biologic agents in the management of non-infectious uveitis.Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.Emerging drugs for the treatment of uveitis.Urban legend series: mucous membrane pemphigoid.Treatment of uveitis associated with juvenile idiopathic arthritis.

P2860

Q24630848-91857D2B-DB6F-44EF-9B25-1068E92621E8 Q26766611-F5ACB67E-44C3-41C9-97ED-20E8ACF2A0EC Q26798201-FCA42B44-F14F-4A60-B11A-D58402562748 Q27025862-C0A4A2B5-1945-4C77-BE76-CB6B53F51F85 Q27693189-AF75D0D1-120E-4A39-B24B-23E4262586F3 Q30468406-41C8A774-FF4E-47F0-A1E5-61563750337D Q33615686-EB621E85-EA57-45CC-B4FB-953843539E8D Q33910781-4922E540-73D3-44A0-AA76-DB743CFDA52E Q34208099-B68213FB-4B8D-4DFC-B550-81891F7AB962 Q34257553-605BF2CD-C1FE-4A23-B335-598B71FF3613 Q34274075-62688132-FF60-4C68-93E7-E251883F9312 Q34444734-6034E50A-BDF9-4880-8303-595CE1A11131 Q34623981-25E30C67-139D-4246-86D9-75D4A07CC92D Q34627012-78EC6D2A-3F98-444F-8945-DBD221C55F03 Q34786343-83450497-FB42-49C5-88CD-8D39AF852EA8 Q34789195-5ED751AE-FF2D-49E9-B849-B3EE13AC2B94 Q35208743-2CC8D01E-FE80-4755-B4DC-D04F95C90E14 Q35233322-DD364603-50E3-4076-86EA-B0356C0E916D Q35237628-37DA4664-885D-471D-B5F6-D87949640DB5 Q35681664-7544040E-5F0F-4CC9-B2EA-CAD8A8507CB1 Q35828102-0FD657FF-05A3-4684-BC17-8E86B70B5BD0 Q35835623-22FEB687-F406-47E0-8705-6AEC1EC70B1A Q35895632-F26F5417-5D34-4992-B2C6-6434D3853154 Q36236321-5D7361B0-5E76-415D-83AB-C2424E9805B5 Q36297036-97E6B612-A929-4BD9-8559-0C6F6B39A676 Q36584169-2DAA90F3-1F7F-4871-8411-19480AD7A76F Q36707183-C57CE86B-35DA-43E3-AEDF-B119D3C4913E Q37095406-D27173D4-926C-4B72-84FF-4B26E80E04E0 Q37245815-AD750E6C-41F1-4C1B-8315-3F99DFD93BE5 Q37256887-B40BBA66-92D3-4FB3-A674-CDBFE723D3EF Q37361391-5903DDBB-F128-478E-9992-37D38C75E961 Q37466204-28EA3E6C-ECE4-49C3-A786-BA2ABE380EA2 Q37600483-DE475A2D-5E09-478E-96EA-790422EA11B6 Q37936459-AF7C9DA8-6939-4C02-855C-E3C18B98D6BF Q37992705-7CBDACE4-D536-4217-ABC8-6E94B3C39D38 Q38025152-78E24071-9C15-4DBE-8C71-5619E2F9B479 Q38092131-B02FE753-26AE-42D3-9D37-281E5C61733B Q38166016-75EB49DC-EFD0-468A-8E02-8177CC998528 Q38169809-59E813C1-7190-477C-82BD-10A538ABF894 Q38221012-B72DB723-9A3E-481C-96F7-FBFF6EABF378

P2860

Mycophenolate mofetil for ocular inflammation.

http://www.wikidata.org/entity/Q33521396

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Mycophenolate mofetil for ocular inflammation.

@ast

Mycophenolate mofetil for ocular inflammation.

@en

Mycophenolate mofetil for ocular inflammation.

@nl

type

label

Mycophenolate mofetil for ocular inflammation.

@ast

Mycophenolate mofetil for ocular inflammation.

@en

Mycophenolate mofetil for ocular inflammation.

@nl

prefLabel

Mycophenolate mofetil for ocular inflammation.

@ast

Mycophenolate mofetil for ocular inflammation.

@en

Mycophenolate mofetil for ocular inflammation.

@nl

P1433

Q33521396-47D386AC-43AE-4369-B43A-61CB2E0AA963

P1476

Q33521396-4CA2A361-E7DF-4CB1-B94B-6D245BDBE93C

P2093

Q33521396-378C0A94-AEDE-42B6-9517-E9F0B3547A94

Q33521396-37950EE6-5B4F-4ECF-A8F1-549DA58F50ED

Q33521396-5A713789-459C-4700-8D2D-3A6AD724E800

Q33521396-7CE70EE1-B562-4AC4-B13E-B6418AE87080

Q33521396-A3C90EE9-FB7B-47F8-BA8B-06B0839F1D9C

Q33521396-E5DD5387-9D38-4C08-80F6-F213854C41DB

Q33521396-E83EBA74-FEBC-4FD9-B293-FB523A504AE7

Q33521396-F2C02FB3-022A-48D8-AE7E-A7777B9206B5

Q33521396-FB788438-C8C5-452E-9AA1-07CCB31582F7

P2860

Q33521396-00DC9111-4E3B-4646-8060-34202FC1E472

Q33521396-0E62041F-CFA9-4F42-A08D-B3E10393C1EE

Q33521396-1F9A58C9-6BA4-4BB7-9C0B-FFC2A97CEFC0

Q33521396-2326DD91-D277-46CB-94F9-4A02F30CB743

Q33521396-2C436475-7C0A-43C1-9BFB-C18E9777AFD8

Q33521396-38A06CF0-6145-4002-852A-5F451DE89B64

Q33521396-3C07AF34-D8CA-4E7A-8FE2-BA4EB4835FA3

Q33521396-3C3FCA92-06FC-4A61-8AB1-1749C5ED5CCD

Q33521396-52DF0682-85DF-4AD1-B685-2EF866800AC0

Q33521396-590F8419-D077-471A-949A-0E5EA9ADD8D5

P304

Q33521396-EE5C3660-E24D-4ECC-9F0B-223E603C9AA6

P31

Q33521396-C6B64221-7640-4781-B53A-2C8ACF7BFFE0

P356

Q33521396-5012695F-1795-40D4-80F1-A3429106CC32

P407

Q33521396-D4528500-BE1A-42A9-8F49-49D85632D675

P433

Q33521396-07A08072-BA83-4B97-BD2F-625C1035304B

P478

Q33521396-9BC46C1E-7C47-4FB8-8CC5-00ABE85A4D51

P50

Q33521396-6B132547-18F7-4A04-8E32-DA7D614AD38A

Q33521396-7C30DBED-E469-4AE0-991A-D14FAB8DE3CA

Q33521396-AB709FD5-D71B-4C28-877B-1AB8F33E5E74

P577

Q33521396-AB898872-B0DF-4489-9F3E-20545FCE5CC9

P5875

Q33521396-E8C54AC5-BA14-4F88-9BB9-B8CFC55C8432

P698

Q33521396-BEA5AC7A-3EC6-496E-AEF7-A255A218F744

P921

Q33521396-3DBF1D33-69C1-48D0-9112-3F34B2B6D974

P932

Q33521396-F5D70B31-7A75-422A-A9DA-3C041A0F56CB

P356

J.AJO.2009.09.026

P1433

American Journal of Ophthalmology

P1476

Mycophenolate mofetil for ocular inflammation.

@en

P2093

C Stephen Foster

http://www.w3.org/2001/XMLSchema#string

Craig W Newcomb

http://www.w3.org/2001/XMLSchema#string

Douglas A Jabs

http://www.w3.org/2001/XMLSchema#string

Eric B Suhler

http://www.w3.org/2001/XMLSchema#string

James T Rosenbaum

http://www.w3.org/2001/XMLSchema#string

Jennifer E Thorne

http://www.w3.org/2001/XMLSchema#string

John H Kempen

http://www.w3.org/2001/XMLSchema#string

R Oktay Kaçmaz

http://www.w3.org/2001/XMLSchema#string

Siddharth S Pujari

http://www.w3.org/2001/XMLSchema#string

P2860

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

Characterization of human type I and type II IMP dehydrogenases

Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.

Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

Mycophenolate mofetil-induced neutropenia in liver transplantation.

Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.

Mycophenolate mofetil in the treatment of uveitis in children

Mechanisms of action of mycophenolate mofetil.

P304

423-32.e1-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJO.2009.09.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

149

http://www.w3.org/2001/XMLSchema#string

P50

Robert B Nussenblatt

Grace A Levy-Clarke

P577

2009-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40819164

http://www.w3.org/2001/XMLSchema#string

P698

20042178

http://www.w3.org/2001/XMLSchema#string

P921

P932

2826576

http://www.w3.org/2001/XMLSchema#string